AGL 41.50 Increased By ▲ 2.96 (7.68%)
AIRLINK 128.00 Decreased By ▼ -1.50 (-1.16%)
BOP 6.26 Increased By ▲ 0.65 (11.59%)
CNERGY 4.13 Increased By ▲ 0.27 (6.99%)
DCL 8.44 Decreased By ▼ -0.29 (-3.32%)
DFML 40.69 Decreased By ▼ -1.07 (-2.56%)
DGKC 87.90 Decreased By ▼ -0.40 (-0.45%)
FCCL 34.10 Decreased By ▼ -0.90 (-2.57%)
FFBL 66.33 Decreased By ▼ -1.02 (-1.51%)
FFL 10.56 Decreased By ▼ -0.05 (-0.47%)
HUBC 108.70 Decreased By ▼ -0.06 (-0.06%)
HUMNL 14.46 Decreased By ▼ -0.20 (-1.36%)
KEL 4.65 Decreased By ▼ -0.10 (-2.11%)
KOSM 7.33 Increased By ▲ 0.38 (5.47%)
MLCF 42.72 Increased By ▲ 1.07 (2.57%)
NBP 60.84 Increased By ▲ 1.24 (2.08%)
OGDC 178.97 Decreased By ▼ -4.03 (-2.2%)
PAEL 25.70 Decreased By ▼ -0.55 (-2.1%)
PIBTL 6.06 Increased By ▲ 0.09 (1.51%)
PPL 146.15 Decreased By ▼ -0.55 (-0.37%)
PRL 24.91 Increased By ▲ 1.30 (5.51%)
PTC 16.14 Decreased By ▼ -0.42 (-2.54%)
SEARL 70.20 Increased By ▲ 1.90 (2.78%)
TELE 7.22 Decreased By ▼ -0.01 (-0.14%)
TOMCL 36.20 Increased By ▲ 0.25 (0.7%)
TPLP 7.84 Decreased By ▼ -0.01 (-0.13%)
TREET 15.59 Increased By ▲ 1.39 (9.79%)
TRG 50.36 Decreased By ▼ -0.09 (-0.18%)
UNITY 26.90 Increased By ▲ 0.15 (0.56%)
WTL 1.24 Increased By ▲ 0.03 (2.48%)
BR100 9,795 Decreased By -11.1 (-0.11%)
BR30 29,647 Decreased By -31.2 (-0.1%)
KSE100 92,021 Decreased By -282.9 (-0.31%)
KSE30 28,665 Decreased By -175.5 (-0.61%)

Pakistan’s pharmaceutical company BF Biosciences Limited (BFBL) has secured approval from the Drug Regulatory Authority of Pakistan (DRAP) for brownfield expansion.

The development was shared by its parent Ferozsons Laboratories Limited in a notice to the Pakistan Stock Exchange (PSX) on Monday.

“We are pleased to inform that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has secured approval from the Drug Regulatory Authority of Pakistan (DRAP) for its brownfield expansion (Line II) which includes: pre-filled syringes line; liquid and lyophilized line; and product development section,” read the notice.

BF Biosciences enters into agreement with Lucky Core Industries

The pharmaceutical informed that the commercial production from pre-filled syringes line has commenced, whereas the liquid and lyophilized line is under internal validation and will start commercial production from the second quarter of FY 2024- 25.

BF Biosciences Limited also shared that it has launched Sematide (Semaglutide) in pre-filled syringe.

“Sematide is the first Glucagon-Like Peptide 1 (GLP1) receptor agonist approved for local manufacture in Pakistan, offering a convenient solution for diabetes management,” informed the company, adding that Sematide is being manufactured at the new state-of-the-art European prefilled syringes line of BF Biosciences Limited.

Following the launch of Ferulin (Human Insulin), the launch of Sematide (Semaglutide) at an affordable price, marks a significant step in our commitment to stop diabetes.

“We are confident that Ferulin and Sematide will have a positive impact on our subsidiary’s growth and will further strengthen our mission to address unmet patient needs.

BF Biosciences Limited added that that the Securities and Exchange Commission of Pakistan (SECP) and Pakistan Stock Exchange (PSX) has approved its listing application.

The company is planning an initial public offering (IPO) at the PSX, aiming to raise at least Rs1.375 billion ($4.94 million) by issuing 25 million shares at a floor price of Rs55 per share.

Comments

200 characters
Salim Sep 09, 2024 03:11pm
All this is being done to create hype for rate increase. Study Ciity Pharma and you will come to know.
thumb_up Recommended (0) reply Reply
Waqar Akram Sep 09, 2024 05:14pm
@Salim, What are you trying to propose?
thumb_up Recommended (0) reply Reply